McNeil Consumer Healthcare

In a LinkedIn post Monday, Ashley McEvoy lauded her time at Johnson & Johnson, and particularly her final role leading the medtech team, as “the honor and privilege of my career.” After spending the better part of the last three decades at Johnson & Johnson, Ashley McEvoy, worldwide chairman of its medtech franchises, will be charting a new course. McEvoy informed J&J late last week of her plans to leave, according to an announcement published by the company Monday afternoon. She’ll stay on at J&J MedTech into the first quarter of next year to ensure that her successor’s transition into the role is a smooth one—and she hasn’t yet publicly shared the details of the “new opportunities” she’ll soon be pursuing. Filling her shoes at the top of the $27 billion medtech business will be Tim Schmid, another three-decade veteran of J&J and most recently the company group chairman of the medtech division’s Asia-Pacific business. “I want to thank Ashley for her leadership and 27 years of service at Johnson & Johnson. She has led significant transformation of our MedTech business resulting in improved performance and allowing us to better meet the needs of patients and consumers around the world,” J&J CEO Joaquin Duato said in the announcement. “Her leadership of people and commitment to their development has been a hallmark of her tenure. I wish her all the best in the next chapter of her career.” McEvoy joined J&J in 1996 and spent the first 10 years of her tenure in the consumer health division, including a stint as president of what was then known as McNeil Consumer Healthcare. She transferred to the medical devices department in 2009 to become worldwide president of the surgical technology subsidiary Ethicon before being named company group chairman of vision and diabetes care in early 2012. She took on her current role at the helm of J&J MedTech in June 2018, and, last year, she joined the ranks of J&J’s highest-paid executives, as her nearly $7.4 million 2022 payout earned her a spot on the company’s annual disclosure of its five top-paid execs. In a LinkedIn post Monday, McEvoy lauded her time at J&J, and particularly her final role leading the medtech team, as “the honor and privilege of my career.” “Stepping back, it’s impossible to overstate how important this company has been to me and how grateful I am for my career here. I can still remember when I started at J&J at age 26 as an assistant product director on Tylenol," McEvoy said. "In the time since, I’ve had the career of a lifetime, leading five companies within J&J and raising five children along the way,” she wrote. “I’ve always taken on new challenges, driven by curiosity, a deep and lifelong passion for healthcare and making it possible for people to lead better lives—and this company has allowed me to do that beyond my greatest imagination.” “I’m excited to continue to pursue that passion and for what the next chapter will bring. But for now, I want to take a moment to say thank you to my team—for your hard work, talent, and for your unwavering commitment to transforming the future of healthcare.” McEvoy’s post also shouted out Schmid: “Tim is more than just my successor, he is a trusted friend and partner,” she wrote. “When I had my fourth child, Tim ran the business while I was on leave, and when I went to run Vision, he backfilled my role as Worldwide President of Ethicon, so it’s both fitting and meaningful that I am passing the baton to him now.” Schmid joined J&J in 1993 through its sales department. He spent more than a decade in its since-divested LifeScan blood glucose monitoring business before moving to Ethicon in 2009. He was named chief strategic customer officer of the medtech division in 2016, a role he held for nearly three years before being tapped to lead the division’s Asia-Pacific operations in late 2018.

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) (the Company) announced today that Ashley McEvoy, Executive Vice President, Worldwide Chairman of MedTech, informed the company on October 20, 2023, that she is stepping down from her position to pursue other opportunities. Ms. McEvoy will remain with the Company into Q1 2024 to support a successful transition. Tim Schmid has been appointed Executive Vice President, Worldwide Chairman of MedTech, joining the Company’s Executive Committee. Ms. McEvoy joined Johnson & Johnson 27 years ago in the Consumer Products Group, where she oversaw classic brands including Tylenol® and Zyrtec® and grew her career to serve as President of McNeil Consumer Healthcare. Ms. McEvoy moved to MedTech in 2009 where she served as Worldwide President of Ethicon and then advanced to become Company Group Chairman of Vision and Diabetes Care prior to assuming her current role. Ms. McEvoy is presently serving as chair of the AdvaMed board of directors, the leading global trade association and consortium of companies for the medical devices industry and also serves on the Board of Trustees for the Children’s Hospital of Philadelphia (CHOP). “I want to thank Ashley for her leadership and 27 years of service at Johnson & Johnson. She has led significant transformation of our MedTech business resulting in improved performance and allowing us to better meet the needs of patients and consumers around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “Her leadership of people and commitment to their development has been a hallmark of her tenure. I wish her all the best in the next chapter of her career.” Ms. McEvoy’s passion for people and development of leaders has enabled the Company to confidently transition the sector leadership to Mr. Schmid, a respected, skilled, and tested, Credo-based MedTech leader. With 30 years of Johnson & Johnson experience, Mr. Schmid most recently served as the Company Group Chairman of Johnson & Johnson MedTech Asia Pacific (APAC). During his tenure, the APAC region has delivered above market growth and further strengthened our leadership position across multiple businesses. Mr. Schmid has also been instrumental in elevating the role of the region as a growing center for MedTech experimentation, digital innovation, and talent. Mr. Schmid has held a variety of diverse leadership positions in sales, strategic marketing and general management across multiple businesses and geographies, including Chief Strategic Customer Officer for Johnson & Johnson MedTech, where he helped lead transformational changes to Johnson & Johnson’s business-to-business relationships with health systems in the U.S. “We are pleased to have the depth of talent at Johnson & Johnson that allows us to transition to Tim, a respected, results-driven and Credo-based leader,” said Duato. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at . Cautions Concerning Forward-Looking Statements This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. A list and description of risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at , or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. View source version on businesswire.com: Contacts Investor Relations: Jessica Moore Investor-relations@its.jnj.com Source: Johnson & Johnson View this news release online at:

Expansion in geriatric populace, ascend in the pervasiveness of gastrointestinal problems, and flood in the quantity of pipeline drugs have supported the development of the worldwide touchy irritable bowel syndrome treatment market Allied Market Research as of late distributed a report, named, "Irritable bowel syndrome treatment Market by Type (IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), and Mixed (IBS-M), Product (Rifaximin, Eluxadoline, Lubiprostone, Linaclotide, and Others), and End User (Hospitals Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies): Global Opportunity Analysis and Industry Forecast, 2019–2026". As per the report, the worldwide irritable bowel syndrome treatment industry was fixed at $1.07 billion out of 2018 and is relied upon to reach $2.01 billion by 2026, enrolling a CAGR of 8.2% from 2019 to 2026. Motivators for market development Expansion in geriatric populace, ascend in the pervasiveness of gastrointestinal problems, and flood in the quantity of pipeline drugs have supported the development of the worldwide touchy irritable bowel syndrome treatment market. Nonetheless, helpless interest from immature nations hampers the market development. In actuality, undiscovered potential in the creating economies is relied upon to set out worthwhile open doors soon. Request Sample Report at: The rifaximin section ruled the market Result, the Rifaximin portion held the biggest offer in 2018, represented more than 33% of the worldwide peevish gut condition treatment market. In addition, the fragment is relied upon to enlist the biggest CAGR of 9.4% during the gauge time frame, because of expanded interest to treat IBS with Diarrhea (IBS-D) brought about by Escherichia coli (E. coli) microscopic organisms in grown-ups and kids. The report incorporates an examination of different sections like Eluxadoline, Lubiprostone, Linaclotide, and others. The online drug stores section to show the quickest CAGR through 2026 The online drug stores section is expected to enroll the quickest CAGR of 9.9% from 2019 to 2026, attributable to ascend in inclination for web based buying of medications over the conventional techniques, flood in mindfulness with respect to online drug stores, and expansion in the quantity of Internet clients. Notwithstanding, the pharmacies and retail drug stores section held the biggest offer in 2018, representing the greater part of the worldwide crabby gut condition treatment market, because of solid presence of retail drug stores all throughout the planet and the accommodation offered by them. North America held the overwhelming majority The worldwide peevish entrail condition therapy market across North America held the biggest offer in 2018, representing almost 50% of the market, attributable to ascend in gastrointestinal sicknesses like stomach torment, loose bowels, and obstruction and presence of cutting edge medical care offices with prepared clinical experts. Nonetheless, the market across the Asia-Pacific locale is projected to enlist the quickest CAGR of 9.9% during the estimate time frame. This is because of progress in medical services foundation, ascend in the quantity of emergency clinics furnished with cutting edge clinical offices, presence of the creating R&D area, and expansion in medical care changes. Major market players Abbott Laboratories Ardelyx Inc. Allergan plc AstraZeneca plc Astellas Pharma Inc. Johnson & Johnson (McNeil Consumer Healthcare) GlaxoSmithKline Plc Sebela Pharmaceuticals Inc. Novartis AG Takeda Pharmaceutical Company Ltd. We have also published few syndicated market studies in the other trending area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market. Trending Reports: U.S. Thrombectomy Devices Market: Opportunity Analysis and Industry Forecast, 2018 - 2025 U.S. Biliary Stents Market: Opportunity Analysis and Industry Forecast, 2018 – 2025 About Us Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry. Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1(855)550-5975 help@alliedmarketresearch (dot) com